Synapse February 2013 focuses on injunctions against pharma patent infringement
In Synapse February 2013, Taylor Wessing discusses the issue of interim injunctions against pharmaceutical patent infringement. Synapse focuses on law for the life sciences industry.
The patent system gives innovators a monopoly right — a right that in the life science and pharmaceutical sector can be extremely valuable. It is perhaps unsurprising therefore that a manufacturer will go to some lengths to enforce their patent rights protecting a product.
A powerful tool for this purpose is the injunction, which — if deployed correctly — can stop a potential infringer in their tracks.
Other topics covered in Synapse February 2013 include: the Transparency Directive and the customs regulation.
To read more click here.
News from Taylor Wessing
Taylor Wessing advises iCITY and Infinity in landmark Olympic legacy deal
Taylor Wessing's GIPI team introduces intellectual property survey
Taylor Wessing appoints Sanjvee Shah to its private client practice
Mark Owen joins Taylor Wessing's international TMT group
Taylor Wessing advises Hyperion on sale of shares to General Atlantic
News from The Lawyer
Speechly Bircham and Withers merger vote just days away
Is it you? The Lawyer Awards shortlist unveiled
BLP wins as CoA looks to Russian law in key matrimonial case
Revealed: A&O takes biggest hit as magic circle squanders £10m on lost trainees
Taylor Wessing favours global network in 16-strong promos round
Briefings from Taylor Wessing
Court of Appeal allows preliminary injunction pending appeal of invalidity
The Court of Appeal has allowed Novartis’s application for a preliminary injunction against Hospira.
Taylor Wessing publishes legal guide to the UK consumer products sector
This guide shares the key trends that Taylor Wessing is seeing in the UK consumer products sector.
Analysis from The Lawyer
Crunch boom
Financial disputes are starting to dominate the English courts as the long-awaited fallout from the downturn finally comes to town
Patent by numbers
A single patent court system for Europe and the high-profile ‘phone wars’ are putting IP at the heart of clients’ business strategies
